Concepedia

Milo Frattini

MF

Statistics

Publications

78

Citations

11.3K

H-Index

41

Active since

1999

Affiliations

Istituto Cantonale di Patologia(Current)

Fondazione IRCCS Istituto Nazionale dei Tumori

IFOM

Ospedale San Giovanni Bellinzona

Institute of Oncology Research

Milo Frattini is an author at Istituto Cantonale di Patologia specializing in oncology, molecular oncology, and medicine.

ORCID

Publications per year

1999–2024

78

Publications

78

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

, , +13

Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Federica Di Nicolantonio, Miriam Martini, Francesca Molinari et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text

, , +17

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio et al. · JAMA · 2010 · 747 citations

, , +17

<i>PIK3CA</i> Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

Andrea Sartore‐Bianchi, Miriam Martini, Francesca Molinari et al. · Cancer Research · 2009 · 739 citations

, , +17

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

Milo Frattini, Piercarlo Saletti, Elena Romagnani et al. · British Journal of Cancer · 2007 · 538 citations · Full text

, , +17

1–5 of 78